Incyte and Genesis Partner on AI-driven Small Molecule Drug Discovery
American multinational pharma company Incyte and AI-focused biotech Genesis Therapeutics have announced a strategic collaboration to leverage artificial intelligence for
Read moreAmerican multinational pharma company Incyte and AI-focused biotech Genesis Therapeutics have announced a strategic collaboration to leverage artificial intelligence for
Read moreVariant Bio, a leading genomics-driven drug discovery company, announced today it is entering a new, multi-year research collaboration with pharmaceutical
Read moreInsitro, a leading AI-driven drug discovery and development company, has entered into three strategic agreements with Eli Lilly and Company
Read moreAI firm Generate:Biomedicines announced on Tuesday that it has secured a $1B+ collaboration with Novartis to advance AI-driven protein therapeutics.
Read moreSangamo Therapeutics Enters License Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases Sangamo Therapeutics, Inc., a leader in
Read moreTakeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read moreThe Hamburg headquartered publicly listed drug discovery and development company Evotec and Variant Bio, a US-based biotech company leveraging the
Read moreFrench biotech Medincell announced on Tuesday entering into a collaboration with AbbVie, to co-develop up to six innovative long-acting injectable
Read moreVertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read moreBristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read more